There are more promising ideas in ALS research than ever before, but too few places are equipped to turn them into treatments. This expansion is how we meet that moment. 

After years of accelerating progress, ALS research has reached a turning point: scientific ideas are advancing faster than the systems built to test them.

This is not a challenge facing one organization; it is a constraint on the entire ALS research ecosystem.

Advances in genetics, biomarkers, disease biology, and technology have fundamentally changed what is possible. There are more promising therapeutic ideas and paths forward than ever before—but without sufficient infrastructure and expertise, too many risk slowing or stalling.

ALS TDI was built to address exactly this challenge.

As one of the very few research labs in the world with deep expertise across every stage of ALS drug discovery—from early target discovery to cellular and animal models, biomarkers, and translational science—ALS TDI is uniquely equipped to rigorously test potential therapies and advance the strongest science toward trials.

Now, to meet this pivotal moment, ALS TDI is beginning a landmark expansion.

This expansion will double our research team and establish a new 33,000 sq. ft. laboratory facility—allowing us to test more potential treatments, move faster, and advance the most promising therapies toward clinical trials.

A first look at the 33,000 sq. ft. lab space ALS TDI is building to expand research capacity



Growing to Meet the Moment

Because of this integrated capability, ALS TDI plays a role in ALS research that extends well beyond our own internal programs. In addition to advancing therapies developed in our lab, we are increasingly called upon by academic and industry partners around the world to help evaluate and validate potential ALS treatments.

Our ability to move seamlessly from early discovery through translational testing has made ALS TDI a critical hub for global ALS drug discovery, one of the few places where promising ideas can be tested rigorously, efficiently, and without silos.

That role carries responsibility.

As the pace of discovery continues to accelerate, the number of programs with potential to advance continues to grow. That reality is what drives our decision to expand.


What This Expansion Makes Possible

This expansion is not about growth for growth’s sake. It is about building the capacity required to meet the responsibility ALS TDI now carries within the global research ecosystem.

With the expanded facilities and a growing research team, ALS TDI will be able to:

Accelerate drug discovery

  • Increase the speed and scale of therapeutic screening to advance promising treatments faster.

Move more therapies toward clinical trials

  • Generate the rigorous data and validation needed to support efficient progression to human testing.

Broaden and refine ALS models and tools

  • Develop more advanced disease models to support precise, targeted therapeutic strategies.

Advance more ideas in parallel

  • Pursue multiple therapeutic approaches at once—reducing risk and increasing the likelihood of meaningful breakthroughs.


Built by this Community. Designed for Impact.

This expansion is made possible by a generous commitment from Augie’s Quest to Cure ALS, along with the continued support of the ALS community, whose belief in urgency, rigor, and bold action has always powered our work.

Because of this support, ALS TDI is positioned to become the largest and most impactful ALS-focused drug discovery laboratory in the world, purpose-built to turn scientific opportunity into real treatments.


What Comes Next

The next phase of this expansion is already underway, with the hiring of new scientists and the build-out of an expanded laboratory space at 200 Arsenal Yards Blvd. in Watertown, MA. Each step forward increases our ability to move faster, test smarter, and deliver answers that matter.

Follow our journey for updates as the expansion moves forward!